Allergan Puts Up $958M For Migraine Treatment Maker
Specialty drugmaker Allergan Inc. will fork over $958 million for MAP Pharmaceuticals Inc., the company behind a new treatment for migraine headaches, to beef up its offerings aimed at alleviating the...To view the full article, register now.
Already a subscriber? Click here to view full article